Sort   by:  
 Page size 
LNPs have been demonstrated to hold great promise for the clinical advancement of RNA therapeutics. Continued exploration of LNPs for application in new disease areas requires identification and optimisation of leads in a high throughput way. Currently available high throughput in vivo screening pla...
ORGANISM(S): Mus musculus (Mouse) 
2024-10-17 | PXD053797 | Pride
Next generation modified antisense oligonucleotides (ASOs) are commercially approved new therapeutic modalities, yet poor productive uptake and endosomal entrapment in tumour cells limit their broad application. We compared intracellular traffic of anti KRAS antisense oligonucleotide (AZD4785) in go...
ORGANISM(S): Homo sapiens (Human) 
2021-11-10 | PXD027804 | Pride
Sort   by:  
 Page size